相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Amelioration of ketoconazole in lipid nanoparticles for enhanced antifungal activity and bioavailability through oral administration for management of fungal infections
Narendar Dudhipala et al.
CHEMISTRY AND PHYSICS OF LIPIDS (2020)
Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis
Shabi Parvez et al.
SCIENTIFIC REPORTS (2020)
Solid Lipid Nanoparticles for Drug Delivery: Pharmacological and Biopharmaceutical Aspects
Sebastian Scioli Montoto et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2020)
Development of anti-angiogenic erlotinib liposomal formulation for pulmonary hypertension: a QbD approach
Sagar Dhoble et al.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2019)
The mechanisms of pharmacokinetic food-drug interactions - A perspective from the UNGAP group
Mirko Koziolek et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2019)
Improved oral bioavailability and therapeutic efficacy of erlotinib through molecular complexation with phospholipid
Chander Parkash Dora et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2017)
Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation
Mounika Nooli et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2017)
Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer
Zahra Bakhtiary et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2017)
Development of Solid Self-Emulsifying Formulation for Improving the Oral Bioavailability of Erlotinib
Duy Hieu Truong et al.
AAPS PHARMSCITECH (2016)
Potential of erlotinib cyclodextrin nanosponge complex to enhance solubility, dissolution rate, in vitro cytotoxicity and oral bioavailability
Chander Parkash Dora et al.
CARBOHYDRATE POLYMERS (2016)
Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine
Heidemarie Kletzl et al.
ANTI-CANCER DRUGS (2015)
Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation
Naresh Devasari et al.
CARBOHYDRATE POLYMERS (2015)
β-Hydroxybutyric acid grafted solid lipid nanoparticles: A novel strategy to improve drug delivery to brain
Vinay Kumar Venishetty et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2013)
Oral lipid-based drug delivery systems an overview
Sandeep Kalepu et al.
ACTA PHARMACEUTICA SINICA B (2013)
Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: A novel strategy to avoid intraduodenal administration
Vinay Kumar Venishetty et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2012)
Design, optimization and in vitro evaluation of reverse micelle-loaded lipid nanocarriers containing erlotinib hydrochloride
Sandy Vrignaud et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2012)
The size of solid lipid nanoparticles: An interpretation from experimental design
Carla Vitorino et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2011)
Solid lipid nanoparticles: an oral bioavailability enhancer vehicle
Harshad Harde et al.
EXPERT OPINION ON DRUG DELIVERY (2011)
A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma
Lionel Faivre et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2011)
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
Federico Cappuzzo et al.
LANCET ONCOLOGY (2010)
Lipid Nanoparticles with a Solid Matrix (SLN, NLC, LDC) for Oral Drug Delivery
Marc Muchow et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2008)
Oral bioavailability of cyclosporine:: Solid lipid nanoparticles (SLN®) versus drug nanocrystals
R. H. Mueller et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2006)
Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects
P Frohna et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human
Y Wu et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2004)
分享论文
